论文部分内容阅读
目的针对原发性乳腺淋巴瘤的临床特点及病理情况进行分析,为今后的治疗总结经验,提高治疗效果。方法原发性乳腺淋巴瘤患者20例,对其临床特点及病理情况进行分析。结果在收治的20例原发性乳腺淋巴瘤患者中,全部都是非霍奇金淋巴瘤患者,其中20例患者中有18例为B细胞性,2例为T细胞性,其中在18例B细胞性非霍奇金淋巴瘤患者中,出现弥漫性大B细胞淋巴瘤的患者是15例,黏膜相关淋巴瘤的患者为3例。其中有18例患者接受化学治疗,而另外的2例患者没有进行化疗,本次试验中18例化疗患者大多数采用环磷酰胺+多柔比星+长春新碱+泼尼松(CHOP)方案进行治疗,本次试验中患者的平均生存时间是2~3年,3年的无病生存率是40.38%,5年的无病生存率是26.09%,3年的总生存率是79.38%,5年的总生存率是55.09%。对比结果差异具有统计学意义(P<0.05)。结论通过对原发性乳腺淋巴瘤的临床特点及病理情况进行分析,主要通过常规HE切片观察,尚需要免疫组化进一步证实,作者发现患者大多数是女性,同时最主要的就是弥漫性大B细胞淋巴瘤患者。
Objective To analyze the clinical features and pathology of primary breast lymphoma and to summarize the experience for the future treatment and improve the therapeutic effect. Methods Twenty patients with primary breast lymphoma were analyzed for their clinical features and pathology. Results Of the 20 patients with primary breast lymphoma who were treated, all were non-Hodgkin’s lymphoma patients, of which 20 were B-cell in 20 and T-cell in 2, 18 Of the 15 patients with diffuse large B-cell lymphoma who developed cellular NHL, there were 3 patients with mucosal-associated lymphoma. Among them, 18 patients received chemotherapy and the other 2 patients did not undergo chemotherapy. Most of the 18 chemotherapy patients in this trial adopted cyclophosphamide + doxorubicine + vincristine + prednisone (CHOP) regimen The average survival time of patients in this trial was 2 to 3 years, the 3-year disease-free survival rate was 40.38%, the 5-year disease-free survival rate was 26.09%, the 3-year overall survival rate was 79.38% The 5-year overall survival rate was 55.09%. The difference was statistically significant (P <0.05). Conclusion Through the analysis of the clinical features and pathology of primary breast lymphoma, it is mainly confirmed by routine HE sections that further confirmation by immunohistochemistry is required. The authors found that most of the patients were female and the most important ones were diffuse large B Patients with cell lymphoma.